Bio-Techne (TECH) Return on Capital Employed (2010 - 2026)
Bio-Techne (TECH) posted quarterly Return on Capital Employed of 6.45% for Q1 2026, down 46.0% year-over-year from 11.95% in Q1 2025, and up 31.49% quarter-over-quarter from 4.91% in Q4 2025.
Bio-Techne (TECH) Return on Capital Employed (2010 - 2026) Analysis & Trends
Bio-Techne's Return on Capital Employed history runs 17 years deep, the most recent figure standing at 6.45% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 46.0% year-over-year to 6.45%; the TTM figure through Mar 2026 stood at 6.45% (down 46.0% YoY), while the FY2025 annual figure was 4.17%, down 406.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.45%, up from 4.91% in the prior quarter.
- The five-year high for Return on Capital Employed was 13.98% in Q2 2022, with the low at 4.22% in Q2 2025.
- The 5-year median for Return on Capital Employed is 9.91% (2024), against an average of 9.43%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed jumped 260 bps in 2022, then slumped 422 bps in 2024.
- Bio-Techne's Return on Capital Employed stood at 13.25% in 2022, then declined by 22 bps to 10.3% in 2023, then declined by 24 bps to 7.88% in 2024, then plunged by 38 bps to 4.91% in 2025, then soared by 31 bps to 6.45% in 2026.
- Business Quant data shows TECH's Return on Capital Employed at 6.45% in Q1 2026, 4.91% in Q4 2025, and 4.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 6.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.45% |
| Dec 31, 2025 | 4.91% |
| Sep 30, 2025 | 4.59% |
| Jun 30, 2025 | 4.22% |
| Mar 31, 2025 | 6.91% |
| Dec 31, 2024 | 7.88% |
| Sep 30, 2024 | 7.40% |
| Jun 30, 2024 | 8.10% |
| Mar 31, 2024 | 9.91% |
| Dec 31, 2023 | 10.30% |
| Sep 30, 2023 | 11.62% |
| Jun 30, 2023 | 12.00% |
| Mar 31, 2023 | 12.18% |
| Dec 31, 2022 | 13.25% |
| Sep 30, 2022 | 13.26% |
| Jun 30, 2022 | 13.98% |
| Mar 31, 2022 | 13.33% |
| Dec 31, 2021 | 12.32% |
| Sep 30, 2021 | 11.79% |
| Jun 30, 2021 | 11.74% |